Exagen Inc. (XGN)

Business: Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States.

IPO Date: 19-Sep-2019

CEO, Pres & Director: Mr. Fortunato Ron Rocca

CFO & Corp. Sec.: Mr. Kamal Adawi M.S., MBA

Listing: NASDAQ: XGN

Country: United States

Headquarters: Vista, CA

Website: https://www.exagen.com

Market cap: $94.29 Mln

Revenue (TTM): $23.08 Mln

Earnings (TTM): $-30.91 Mln

Cash: $89.75 Mln

Total Debt: $34.48 Mln

Insider's Holding: 21.35%

Liquidity: Low

52 Week range: $4.15 - 15.44

Shares outstanding: 16,256,100

10 Years Aggregate:

• CFO: $-101.35 Mln
• EBITDA: $-121.73 Mln
• Net Profit: $-144.20 Mln